Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315

Summary

Jason Calacanis interviews Bilal Kharouni, CEO of Ekei Labs, at Founder University Tokyo. They discuss Ekei Labs' epigenetic data platform for longevity drug development, Japan's advantages as a base for a biotech startup (aging society, regenerative medicine law, OIST talent), and company-building topics like product-market fit, funding in Japan vs. the US, and equity culture. The conversation also covers biological age testing, blue zones controversy, right-to-try therapies, and work-life balance in startups.

• Ekei Labs generates high-resolution epigenetic data for drug discovery and cell therapy manufacturing QC, operating as a data generation platform.
• Japan provides a favorable environment with an aging population, fast-track regenerative medicine laws, and a top research institute (OIST) in Okinawa.
• Bilal raised a $1M seed plus startup loans from Japanese regional banks that offer non-dilutive funding, allowing a leaner cap table than in Silicon Valley.
• The company cut a growing direct-to-clinic revenue stream to focus on R&D and building a defensible proprietary data moat, prioritizing long-term value over short-term cash.
• Biological age from consumer wearables and blood tests was critiqued as sometimes gamed or disconnected from real health, whereas epigenetic biomarkers hold more promise for drug development.
• Blue zones research faces controversies (e.g., pension fraud in Italy), but Okinawa shows genuine longevity links to social networks and diet.
• Jason advises founders on exit timing, bar-raiser hiring, intensity vs. sustainability, and ruthless time management, while noting the unique Kaizen improvement culture in Japan.